Upload
ibfconferences
View
526
Download
0
Embed Size (px)
DESCRIPTION
Kevin Buehler of Alcon delivers "Plenary Keynote Lecture" at the 2012 Ophthalmology Innovation Summit in Chicago
Citation preview
1 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
a Novartis company
Unmet Medical Needs in Ophthalmologyand Innovation DeliverablesKevin Buehler
Division Head, Alcon
2 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
Alcon – 3 Different Business Eye Segments
$3.9B
$3.6B
$2.4B
2011 Sales = $10 billion
Pharmaceutical
Surgical
Vision Care
24%
36%
39%
3 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
Today’s Changing World…
Evolving Access to Healthcare
Regulatory / Payers
Demand for Technology
QualityCompliance
4 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
Technology Opportunity Scale
Payer Willingness to Purchase New Technology
Level of Unmet Medical Need within Ophthalmology
Low High
Low High
5 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
Technology Opportunity Scale
Patient Interest to Protect Vision
Low High
Payer Willingness to Purchase New Technology
Level of Unmet Medical Need within Ophthalmology
Low High
Low High
6 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
Technology Opportunity Scale
Patient Interest to Protect Vision
Low High
Payer Willingness to Purchase New Technology
Level of Unmet Medical Need within Ophthalmology
Low High
Low High
Health Economics Value
7 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
Paths of Innovation
“Incremental”
Innovation
“Breakthrough”
Innovation
Standard of Care Change
8 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
Innovation/Ophthalmic ideation should target Unmet Needs
Glaucoma Efficacy (IOP) Improvement
Improved Patient Compliance
Surgical Intervention - Reduce
medication burden
Improve efficacy vs. standard of care
Rx for additional retinal indications
Drug delivery to reduce patient
treatment regimen
Macular Degeneration
Series12012 2017
4%
Series12012 2017
15%
Plus $800M in Surgical
9 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
Innovation/Ophthalmic ideation should target Unmet Needs
Improve clinical (refractive) outcomes
Address presbyopia and astigmatism
Continue to improve safety of procedure
Series12012 2017
8%
Cataract
Improve quality of vision
Improve comfort over wearing period
Address presbyopia
Series12012 2017
5%
Contact Lenses
10 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
1. Idea
2. Prototype
3. Proof of Concept
4. Early Development
5. Full Global Development
6. Global Registration
7. Global Production & Distribution
8. Market Regulatory Maintenance,
Quality & Compliance
Partnerships in innovationFrom idea to peak market presence
Partnership can occur at any time
11 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
1. Idea
2. Prototype
3. Proof of Concept
4. Early Development
5. Full Global Development
6. Global Registration
7. Global Production & Distribution
8. Market Regulatory Maintenance,
Quality & Compliance
Partnerships in innovationFrom idea to peak market presence
Partnership in early stages help build data for desired profile.
Post proof-of-concept is easier to develop
Late partnership focused on accelerating/expanding
commercial plans
12 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
Phases of Value Creation
Product Idea & POC
Completion of Registration clinical studies
Regulatory Approval
Reimbursement
Global Commercial capability
13 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
Value Creation – Early Development Project
Early Stage Project
Solid scientific idea
Proof of concept clinical in man
Sound clinical data design vs. standard of care
Safety package
Stable product design
Simple Payer model / rationale
I.P. approach
Later Stage Project
Solid scientific idea
Proof of concept clinical in man
Sound clinical data design vs. standard of care
Safety package
Stable product design
Payer model to justify price
I.P. coverage / Freedom to operate
Manufacturing ready capability
Registration Clinical Data
Global Reimbursement Data
14 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
Value Exchange
Early Stage Project Later Stage Project
Value to Seller
Technology Value
Development Risk
Regulatory Risk
Reimbursement Risk
Commercial Risk
Technology Value
Development Risk
Regulatory Risk
Reimbursement Risk
Commercial Risk
15 | Unmet Needs In Ophthalmology and Innovation Deliverables | November 8, 2012 | Business Use Only
Always Remember …
Patients are waiting for us …
to address their eye care needs
a Novartis company